PD-L 1 expression in hepatocellular carcinoma : relationship with clinical and pathological features

[1]  Toby C. Cornish,et al.  PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. , 2016, Human pathology.

[2]  T. Yau,et al.  Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[4]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[5]  D. Calvisi,et al.  Lessons from rare tumors: hepatic lymphoepithelioma-like carcinomas. , 2015, World journal of gastroenterology.

[6]  Narasimhan P. Agaram,et al.  Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. , 2015, Human pathology.

[7]  V. Wong,et al.  Lymphoepithelioma-like Hepatocellular Carcinoma: An Uncommon Variant of Hepatocellular Carcinoma With Favorable Outcome , 2015, The American journal of surgical pathology.

[8]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[9]  Roman K. Thomas,et al.  PD-L1 expression in small cell neuroendocrine carcinomas. , 2015, European journal of cancer.

[10]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[11]  Yu Yao,et al.  Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. , 2015, Trends in molecular medicine.

[12]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[13]  Lixia Diao,et al.  Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression , 2014, Nature Communications.

[14]  W. Chapman,et al.  Characterization of inflammatory (lymphoepithelioma-like) hepatocellular carcinoma: a study of 8 cases. , 2014, Archives of pathology & laboratory medicine.

[15]  Lijuan Huang,et al.  The PD-1/PD-Ls pathway and autoimmune diseases. , 2014, Cellular immunology.

[16]  谷口 智憲.  Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells , 2013 .

[17]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[18]  Young Bae Kim,et al.  A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma‐like gene expression trait and epithelial‐mesenchymal transition , 2012, Hepatology.

[19]  E. Goode,et al.  Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer , 2011, The Journal of Immunology.

[20]  최기홍,et al.  Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis , 2011 .

[21]  J. Emond,et al.  Steatohepatitic Hepatocellular Carcinoma (SH-HCC): A Distinctive Histological Variant of HCC in Hepatitis C Virus-related Cirrhosis With Associated NAFLD/NASH , 2010, The American journal of surgical pathology.

[22]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[23]  S. Qiu,et al.  Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[24]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[25]  E. Lesaffre,et al.  The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin , 2006, Histopathology.

[26]  S. Thorgeirsson,et al.  A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells , 2006, Nature Medicine.

[27]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[28]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[29]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[30]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.